STOCK TITAN
  1. Home
  2. Sec-filings
  3. KNSA
  4. [Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

KNSA Form 4: Options at $3.80 & $8.83; sale avg $37.14

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) disclosed a Form 4 showing its Chief Medical Officer executed pre‑planned transactions on 10/31/2025 under a Rule 10b5‑1 plan. The officer exercised options for 36,542 Class A ordinary shares at $3.80 and 46,000 shares at $8.83, then sold 82,542 shares at a weighted average price of $37.14 (trade range: $36.80–$37.675). Following these transactions, the filing reports 61,324 shares beneficially owned directly. The options exercised were fully vested and exercisable.

Positive

  • None.

Negative

  • None.
Insider Paolini John F.
Role CHIEF MEDICAL OFFICER
Sold 82,542 shs ($3.07M)
Approx. gross sale proceeds $3.07M
Approx. exercise cost $545K
Approx. pre-tax spread $2.52M
Type Security Shares Price Value
Exercise Share Option 36,542 $0.00 $0.00
Exercise Share Option 46,000 $0.00 $0.00
Exercise Class A Ordinary Share 36,542 $3.80 $139K
Exercise Class A Ordinary Share 46,000 $8.83 $406K
Sale Class A Ordinary Share 82,542 $37.14 $3.07M
Holdings After Transaction: Share Option — 0 shares (Direct); Class A Ordinary Share — 61,324 shares (Direct)
Footnotes (3)
  1. F1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025.
  2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.80 and $37.675. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  3. F3. The option is fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Paolini John F.
(Last) (First) (Middle)
105 PICCADILLY, SECOND FLOOR
(Street)
LONDON X0 W1J 7NJ
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF MEDICAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Share 10/31/2025 M(1) 36,542 A $3.8 97,866 D
Class A Ordinary Share 10/31/2025 M(1) 46,000 A $8.83 143,866 D
Class A Ordinary Share 10/31/2025 S(1) 82,542 D $37.14(2) 61,324 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option $3.8 10/31/2025 M(1) 36,542 (3) 06/28/2027 Class A Ordinary Share 36,542 $0 0 D
Share Option $8.83 10/31/2025 M(1) 46,000 (3) 09/16/2029 Class A Ordinary Share 46,000 $0 0 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025.
2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.80 and $37.675. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. The option is fully vested and exercisable.
/s/ Douglas Barry, Attorney-in-Fact 11/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR